share_log

藥明康德：2023年環境、社會及管治報告

WUXI APPTEC: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Hong Kong Stock Exchange ·  Apr 26 16:51
Summary by Futu AI
無錫藥明康德新藥開發股份有限公司（藥明康德）發佈了其第六份環境、社會及管治（ESG）報告，涵蓋2023年1月1日至12月31日的績效。報告依據香港聯交所《證券上市規則》附錄C2《環境、社會及管治報告指引》編制，並符合全球報告倡議組織《可持續發展報告標準2021》。報告範圍與年報一致，並由TÜV南德認證檢測（中國）有限公司提供獨立性鑒證服務。報告中，藥明康德展示了其在ESG領域的進展，包括碳排放經濟強度較基準年降低23.2%，能源消耗經濟強度降低19.7%，用水經濟強度降低38.7%。此外，公司正式承諾加入科學碳目標倡議（SBTi），並計劃在未來兩年內設定科學碳目標。報告還強調了藥明康德在社區共建、員工發展、職業健康安全等方面的表現，並獲得明晟ESG AA級領導力評級等多項認可。
無錫藥明康德新藥開發股份有限公司（藥明康德）發佈了其第六份環境、社會及管治（ESG）報告，涵蓋2023年1月1日至12月31日的績效。報告依據香港聯交所《證券上市規則》附錄C2《環境、社會及管治報告指引》編制，並符合全球報告倡議組織《可持續發展報告標準2021》。報告範圍與年報一致，並由TÜV南德認證檢測（中國）有限公司提供獨立性鑒證服務。報告中，藥明康德展示了其在ESG領域的進展，包括碳排放經濟強度較基準年降低23.2%，能源消耗經濟強度降低19.7%，用水經濟強度降低38.7%。此外，公司正式承諾加入科學碳目標倡議（SBTi），並計劃在未來兩年內設定科學碳目標。報告還強調了藥明康德在社區共建、員工發展、職業健康安全等方面的表現，並獲得明晟ESG AA級領導力評級等多項認可。
WUXI PHARMACEUTICAL MING KAND NEW DRUG DEVELOPMENT CO., LTD. (PHARMACEUTICAL MING KAND) HAS PUBLISHED ITS SIXTH ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT COVERING PERFORMANCE FROM JANUARY 1 TO DECEMBER 31, 2023. The report is based on the Environmental, Social and Governance Reporting Guidelines, Appendix C2 of the HKEX Listing Rules and complies with the Sustainable Development Reporting Standards 2021, a global reporting initiative organization. The scope of the report is consistent with the annual report, and independent verification services are provided by TÜV Nande Certification Testing (China) Limited. In the report, Pharma Kund showed its progress in the field of ESG, including a 23.2% decrease in carbon emission economic strength compared to the baseline year, a 19.7% decrease in energy consumption economic strength, and a 38.7% decrease...Show More
WUXI PHARMACEUTICAL MING KAND NEW DRUG DEVELOPMENT CO., LTD. (PHARMACEUTICAL MING KAND) HAS PUBLISHED ITS SIXTH ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT COVERING PERFORMANCE FROM JANUARY 1 TO DECEMBER 31, 2023. The report is based on the Environmental, Social and Governance Reporting Guidelines, Appendix C2 of the HKEX Listing Rules and complies with the Sustainable Development Reporting Standards 2021, a global reporting initiative organization. The scope of the report is consistent with the annual report, and independent verification services are provided by TÜV Nande Certification Testing (China) Limited. In the report, Pharma Kund showed its progress in the field of ESG, including a 23.2% decrease in carbon emission economic strength compared to the baseline year, a 19.7% decrease in energy consumption economic strength, and a 38.7% decrease in water use economic strength. In addition, the company has formally committed to join the Scientific Carbon Targets Initiative (SBTi) and plans to set scientific carbon targets over the next two years. The report also highlights the performance of Ming Kand Pharmaceutical in community building, employee development, occupational health and safety, and has received multiple recognitions including the Ming Sheng ESG AA Leadership Rating.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.